Biopharmaceutical company Bristol Myers Squibb (NYSE: BMY) will be reporting earnings this Thursday before market open. Here’s what investors should know.

Bristol-Myers Squibb beat analysts’ revenue expectations last quarter, reporting revenues of $12.5 billion, up 1.3% year on year. It was an exceptional quarter for the company, with full-year revenue guidance exceeding analysts’ expectations and a solid beat of analysts’ revenue estimates.

Is Bristol-Myers Squibb a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting Bristol-Myers Squibb’s revenue to decline 4.5% year on year, improving from the 5.5% decrease it recorded in the same quarter last year.

Heading into earnings, analysts covering the company have grown increasingly bullish with revenue estimates seeing in majority upward revisions over the last 30 days. Bristol-Myers Squibb has a history of exceeding Wall Street’s expectations.

With Bristol-Myers Squibb being the first among its peers to report earnings this season, we don’t have anywhere else to look to get a hint at how this quarter will unravel for pharmaceuticals stocks. However, there has been positive investor sentiment in the segment, with share prices up 10.8% on average over the last month. Bristol-Myers Squibb is down 2.6% during the same time .

WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.

This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.